Telbivudine

Category	Hepatitis B Virus (HBV)
CAS	3424-98-4
Description	Telbivudine is an antiviral drug used in the treatment of hepatitis B infection. It is marketed by Swiss pharmaceutical company Novartis under the trade names Sebivo (Europe) and Tyzeka (United States). Clinical trials have shown it to be significantly more effective than lamivudine or adefovir, and less likely to cause resistance.

Quotation Now

Synonyms	LDT 600; LD-T600; LDT600; Telbivudine; Tyzeka; Epavudine
IUPAC Name	1-[(2S,4R,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione
Molecular Weight	242.23
Molecular Formula	C10H14N2O5
Canonical SMILES	CC1=CN(C(=O)NC1=O)C2CC(C(O2)CO)O
InChI	InChI=1S/C10H14N2O5/c1-5-3-12(10(16)11-9(5)15)8-2-6(14)7(4-13)17-8/h3,6-8,13-14H,2,4H2,1H3,(H,11,15,16)/t6-,7+,8-/m1/s1
InChIKey	IQFYYKKMVGJFEH-GJMOJQLCSA-N
Melting Point	185-186 °C
Purity	98%
Density	1.452 g/cm3
Solubility	Soluble in Water (10 mg/mL)
Appearance	White to Off-White Solid
Application	Antiviral Agents
Storage	Store at -20°C
Complexity	381
Exact Mass	242.09027155
Index Of Refraction	1.584
In Vitro	Telbivudine reverses B19V-induced dysregulation of BIRC3, thus, intervening in the Apoptosis pathway and protecting susceptible cells from cell death.
PSA	104.55000
Target	HBV
XLogP3-AA	-1.2